Preparation of HSV-IgM human-mouse chimeric antibody and development of stable recombinant cell line
In order to achieve large-scale production of HSV-IgM (HSV1, HSV2) human-mouse chimeric antibody in vitro, the gene sequence of the corresponding hybridoma cell was harvested by RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) technique to clone the chimeric antibody into eukaryotic expression vectors, and express the target proteins in CHO-S cells. At the same time, the screening process of stable cell lines was optimized, and the pressure conditions of pool construction stage and monoclonal screening stage were explored. Finally, the target protein was purified by protein L affinity purification method and the biological activity was detected. The recombinant IgM antibodies, HSV1 and HSV2, weighted at 899 kDa and 909 kDa respectively, were prepared. The optimal screening pressure was 20P200M (the first phase of pressure) and 50P1000M (the second phase of pressure). The final titer for the monoclonal expression of HSV1-IgM and HSV2-IgM was 1 620 mg/L and 623 mg/L, respectively. This study may facilitate the development of quality control products of HSV1 and HSV2 IgM series recombinant antibodies as well as efficient expression of IgM subtype antibodies in vitro.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Sheng wu gong cheng xue bao = Chinese journal of biotechnology - 39(2023), 9 vom: 25. Sept., Seite 3887-3898 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Cui, Yamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 09.10.2023 Date Revised 18.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.13345/j.cjb.220912 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362994528 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362994528 | ||
| 003 | DE-627 | ||
| 005 | 20231226092414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.13345/j.cjb.220912 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362994528 | ||
| 035 | |a (NLM)37805862 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Cui, Yamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation of HSV-IgM human-mouse chimeric antibody and development of stable recombinant cell line |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In order to achieve large-scale production of HSV-IgM (HSV1, HSV2) human-mouse chimeric antibody in vitro, the gene sequence of the corresponding hybridoma cell was harvested by RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) technique to clone the chimeric antibody into eukaryotic expression vectors, and express the target proteins in CHO-S cells. At the same time, the screening process of stable cell lines was optimized, and the pressure conditions of pool construction stage and monoclonal screening stage were explored. Finally, the target protein was purified by protein L affinity purification method and the biological activity was detected. The recombinant IgM antibodies, HSV1 and HSV2, weighted at 899 kDa and 909 kDa respectively, were prepared. The optimal screening pressure was 20P200M (the first phase of pressure) and 50P1000M (the second phase of pressure). The final titer for the monoclonal expression of HSV1-IgM and HSV2-IgM was 1 620 mg/L and 623 mg/L, respectively. This study may facilitate the development of quality control products of HSV1 and HSV2 IgM series recombinant antibodies as well as efficient expression of IgM subtype antibodies in vitro | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CHO-S cell | |
| 650 | 4 | |a construction technology | |
| 650 | 4 | |a expression | |
| 650 | 4 | |a human-mouse chimeric IgM antibody | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 700 | 1 | |a Tian, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Qiaohui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guilin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Sheng wu gong cheng xue bao = Chinese journal of biotechnology |d 1997 |g 39(2023), 9 vom: 25. Sept., Seite 3887-3898 |w (DE-627)NLM093700067 |x 1872-2075 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:9 |g day:25 |g month:09 |g pages:3887-3898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.13345/j.cjb.220912 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 9 |b 25 |c 09 |h 3887-3898 | ||